TSS
SER icon

Two Sigma Securities’s Serina Therapeutics SER Stock Holding History

Two Sigma Securities’s Portfolio SER Stock Details SER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-309
Closed -$6K – 3200
2022
Q2 		$6K Buy
+309
New +$8.34K ﹤0.01% 2103

Other funds holding SER

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Securities's SER Position: Q3 2022 in Review

Two Sigma Securities sold out of Serina Therapeutics (SER) in Q3 2022, closing a stake of 309 shares — an estimated $6K sold.

Two Sigma Securities first reported a position in SER in Q2 2022 and held it in 1 quarter. The position peaked at $6K in Q2 2022. 31 funds tracked by Wall St. Rank hold SER as of Q3 2022.

  • Two Sigma Securities reported no remaining Serina Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Two Sigma Securities sold 309 Serina Therapeutics shares in Q3 2022, an estimated $6K.
  • Two Sigma Securities first reported a position in Serina Therapeutics in Q2 2022 and held it in 1 quarter.
  • Two Sigma Securities's Serina Therapeutics position peaked at $6K in Q2 2022.
  • 31 funds tracked by Wall St. Rank held Serina Therapeutics as of Q3 2022.

Based on Two Sigma Securities's 13F filing for Q3 2022, filed 14 Nov 2022.